Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

The Asia Pacific secondhand goods market is growing rapidly due to increased demand for sustainable, affordable products and the rise of online platforms.

The Film and Publication Board details an uptick in online child porn material, with research showing cyber bullying is also ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...